Skip to main content
Journal cover image

Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases.

Publication ,  Journal Article
Papamichael, K; Clarke, WT; Vande Casteele, N; Germansky, KA; Feuerstein, JD; Melmed, GY; Siegel, CA; Irving, PM; Cheifetz, AS
Published in: Clin Gastroenterol Hepatol
April 2021

Comparison data regarding anti-tumor necrosis factor drug concentrations in inflammatory bowel disease (IBD) between the enzyme-linked immunosorbent assay (ELISA) and the homogenous mobility shift assay (HMSA) are scarce.1-3 As decisions in clinical practice depend on the thresholds that define a therapeutic drug concentration, it is important to determine if this varies based on the type of assay used for therapeutic drug monitoring.4 We recently showed a discrepancy between a commercially available ELISA and the HMSA for both infliximab and adalimumab concentrations in patients with IBD.5 Based on the results of the study, Prometheus Laboratories (San Diego, CA) initiated a comprehensive review of their HMSA assays and found that there was an upward drift for both infliximab (from December 2017 to May 2019) and adalimumab (from August 2017 to May 2019), including when our study was performed. Prometheus Laboratories corrected the errant values and reported the revised drug concentrations to physicians (Supplementary Methods). We aimed to compare the corrected infliximab and adalimumab concentrations with the original ELISA values.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Gastroenterol Hepatol

DOI

EISSN

1542-7714

Publication Date

April 2021

Volume

19

Issue

4

Start / End Page

839 / 841.e2

Location

United States

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Inflammatory Bowel Diseases
  • Humans
  • Gastroenterology & Hepatology
  • Enzyme-Linked Immunosorbent Assay
  • Drug Monitoring
  • Adalimumab
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Papamichael, K., Clarke, W. T., Vande Casteele, N., Germansky, K. A., Feuerstein, J. D., Melmed, G. Y., … Cheifetz, A. S. (2021). Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol, 19(4), 839-841.e2. https://doi.org/10.1016/j.cgh.2020.03.002
Papamichael, Konstantinos, William T. Clarke, Niels Vande Casteele, Katharine A. Germansky, Joseph D. Feuerstein, Gil Y. Melmed, Corey A. Siegel, Peter M. Irving, and Adam S. Cheifetz. “Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases.Clin Gastroenterol Hepatol 19, no. 4 (April 2021): 839-841.e2. https://doi.org/10.1016/j.cgh.2020.03.002.
Papamichael K, Clarke WT, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, et al. Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 Apr;19(4):839-841.e2.
Papamichael, Konstantinos, et al. “Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases.Clin Gastroenterol Hepatol, vol. 19, no. 4, Apr. 2021, pp. 839-841.e2. Pubmed, doi:10.1016/j.cgh.2020.03.002.
Papamichael K, Clarke WT, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 Apr;19(4):839-841.e2.
Journal cover image

Published In

Clin Gastroenterol Hepatol

DOI

EISSN

1542-7714

Publication Date

April 2021

Volume

19

Issue

4

Start / End Page

839 / 841.e2

Location

United States

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Inflammatory Bowel Diseases
  • Humans
  • Gastroenterology & Hepatology
  • Enzyme-Linked Immunosorbent Assay
  • Drug Monitoring
  • Adalimumab
  • 3202 Clinical sciences
  • 1103 Clinical Sciences